SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity-Reference-Cited by-同舟云学术

SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity

Published:2020-03-04 Issue:5 Volume:12 Page:4178-4192
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Feng Xiaojun¹,Wang Yanan²,Chen Wenxu²,Xu Suowen³,Li Lingli¹,Geng Yadi¹,Shen Aizong¹⁴,Gao Hui⁵,Zhang Lei¹,Liu Sheng¹

Affiliation:

1. The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, PR. China

2. Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, PR. China

3. Aab Cardiovascular Research Institute, University of Rochester, West Henrietta, NY 14586, USA

4. Anhui Provincial Cardiovascular Institute, Hefei, Anhui, PR. China

5. Department of Pharmacology, School of Medicine, Shaoxing University, Shaoxing, PR. China

Publisher

Impact Journals, LLC

Subject

Cell Biology,Aging

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 4′-O-methylbavachalcone alleviates ischemic stroke injury by inhibiting parthanatos and promoting SIRT3;European Journal of Pharmacology;2024-06

2. Macrod1 suppresses diabetic cardiomyopathy via regulating PARP1-NAD+-SIRT3 pathway;Acta Pharmacologica Sinica;2024-03-08

3. SIRT3 regulates mitochondrial function: A promising star target for cardiovascular disease therapy;Biomedicine & Pharmacotherapy;2024-01

4. Progress in SIRT3 Epigenetics and Pathological Changes in Heart Failure;Medical Diagnosis;2024

5. NAD+: A key metabolic regulator with great therapeutic potential for myocardial infarction via Sirtuins family;Heliyon;2023-11